Why Your Depression Might Not Be a Disease

This is the first of ten essays laying out our Signal Loss Model,a framework for understanding why sophisticated adults develop treatment-resistant conditions, and what interventions actually work. These essays build sequentially, but each stands alone. Read the series in order for the complete framework, or jump in wherever interests you.

The Finding That Changes Everything

In January 2026, Nature published results from a study of 1.2 million people across 14 psychiatric disorders—the most comprehensive analysis of mental health genetics ever conducted. The Psychiatric Genomics Consortium examined everything from schizophrenia to ADHD, autism to substance use disorders, searching for the genetic architecture underlying mental illness.

What they found about depression, anxiety, and PTSD (what researchers call "internalizing disorders") should fundamentally change how we think about treatment.

The headline: These conditions aren't genetically distinct diseases. They're a convergence zone where multiple regulatory systems fail under sustained stress.

The translation: Your depression might not be something you have. It might be something your nervous system is doing when constraint exceeds capacity.

This distinction isn't semantic. It's the difference between "lifelong medication management" and "targeted intervention during neuroplastic windows." Between viewing yourself as broken versus recognizing your system is doing exactly what overstressed regulatory mechanisms do: rigidifying when they should adapt, perseverating when they should update, withdrawing when connection becomes too costly.

Let me show you what the genetics actually reveal, and why it matters for anyone seeking treatment beyond symptom suppression.

What the Genetics Actually Say

The Grotzinger et al. study used cutting-edge statistical modeling to ask: How do psychiatric disorders cluster genetically?

For some conditions, the answer was clear. Schizophrenia and bipolar disorder share substantial genetic architecture. They're variations on a theme. Neurodevelopmental conditions like autism and ADHD cluster together. Substance use disorders form a coherent genetic group.

But internalizing disorders like major depression, PTSD, and anxiety showed something different.

Finding 1: Weak Genetic Boundaries

Depression, anxiety, and PTSD showed the weakest within-cluster coherence of any psychiatric grouping. They cluster together because they represent a common failure mode when regulatory systems can't recalibrate. They do share "depression genes."

Clinical translation: High comorbidity isn't diagnostic confusion. It's the same underlying regulatory failure expressing through different symptom profiles depending on context, history, and current constraints.

Finding 2: The Genes Aren't About Sadness

The genetic variants associated with internalizing disorders don't encode "mood" or "emotion." They're enriched for:

• Threat detection and arousal regulation
• Prediction error signaling (how your brain updates expectations)
• Activity-dependent synaptic plasticity (how circuits rewire through experience)

Clinical translation: These disorders are failures of adaptive recalibration under sustained threat or uncertainty. Your system isn't broken; it's responding appropriately to constraint violation, but the response itself has become maladaptive. No "sadness disease" to report here.

Finding 3: High Polygenicity, Shallow Effect Sizes

Unlike some psychiatric conditions driven by rare, high-impact genetic variants, internalizing disorders show:

• Risk distributed across thousands of genetic variants
• Each variant contributes minimally to overall risk
• Strong environmental modulation

Clinical translation: Genetic risk for depression/anxiety isn't deterministic. It's context-sensitive. Small environmental or experiential interventions can cascade into significant change if they're applied during the right state windows.

Finding 4: These Conditions Are State-Modifiable

The enrichment for activity-dependent plasticity genes (rather than early neurodevelopmental genes) reveals something crucial: internalizing disorders involve regulatory systems that remain responsive to experience throughout the lifespan.

The authors write: "This pattern explains why [...] context, stress load, and learning history matter so much clinically." It also explains why "single-target pharmacology underperforms."

Clinical translation: These conditions are fundamentally treatable through state-dependent interventions: approaches that open neuroplastic windows and install new regulatory patterns while those windows remain accessible.

The Signal Loss Model: Making Sense of the Genetics

These findings converge with what we have observed (and many clinicians have observed for decades), but they also point toward a specific mechanistic explanation. At Nāhua, we call this theSignal Loss Model (SLM) of internalizing disorders.

The core claim is that depression, anxiety, and PTSD aren't discrete diseases but signal loss states: what happens when your nervous system's regulatory capacity is chronically exceeded by environmental or internal demands.

How Signal Loss Develops

Your nervous system maintains homeostasis through multiple regulatory loops:

• Allostatic regulation: Managing physiological resources (cortisol, inflammation, autonomic tone)
• Predictive updating: Refining internal models based on prediction errors
• Embodied selfhood: Maintaining coherent agency and spatial presence
• Social coordination: Balancing connection with autonomic safety

Each system has load capacity. When constraint (threat, uncertainty, relational violation, cognitive overwhelm) exceeds capacity for sustained periods, these regulatory systems don't just fail, they adapt in ways that become self-perpetuating.

The genomic findings explain why this happens:

• Threat/arousal dysregulation genes → Chronic hypervigilance depletes regulatory capacity
• Prediction error signaling genes → Failed updating → perseverative thinking, learned helplessness
• Plasticity genes → Systems that should adapt instead rigidify to conserve resources

Why This Matters for Treatment

If internalizing disorders reflect signal degradation rather than fixed disease states, effective treatment requires:

1. Reducing active constraint (safety, resource access, relational repair)
2. Restoring regulatory capacity (nervous system recalibration, not just cognitive reframing)
3. Installing new patterns during neuroplastic windows (integration work, not just acute experiences)

This is precisely what the Nature paper concludes: "Interventions that reduce threat load, recalibrate prediction, and reorganize embodied self-models are biologically coherent responses."

Most psychiatric treatment does exactly one of these things, usually cognitive reframing or symptom suppression via SSRIs. The genetics suggest why that's insufficient.

The Integration Gap: Why Psychedelic Retreats Fail

Here's where this gets practical. Psychedelics are having a renaissance moment with clinical trials, VC funding, and wellness tourism destinations promising overnight transformations. But if you look at the outcomes data carefully, you'll notice something troubling:

Most people don't sustain the benefits.
Within 6-12 months post-retreat, depression/anxiety scores creep back toward baseline for 60-70% of participants. The acute experiences work exactly as promised: profound insights, ego dissolution, spiritual connection. What fails is the assumption that mystical experience alone installs new regulatory patterns.

The genomic findings explain why:

• Psychedelics open neuroplastic windows (serotonin 2A receptor agonism → BDNF upregulation → enhanced synaptic flexibility)
• But plasticity is directionless; your system will crystallize around whatever patterns are active during the window
• If you return to the same environmental constraints, relational dynamics, and cognitive-behavioral loops that drove regulatory failure in the first place, those are what get reinforced

The implication is that effective psychedelic-assisted therapy requires intensive integration architecture: structured work during the neuroplastic window that actively reshapes threat response, prediction updating, embodied agency, and relational coordination.

This isn't a theoretical nice-to-have. It's mechanistically necessary given what we know about how plasticity works and what the genetic risk factors actually encode.

What Multi-Level Intervention Looks Like

The Nature paper argues explicitly against:

• Single-molecule pharmaceutical fixes
• Purely cognitive reframing
• Diagnosis-first treatment logic

Instead, the genetics point toward multi-level interventions that target:

1. Somatic Recalibration (Embodied Threat Response)

Target: Autonomic dysregulation, spatial disembodiment, postural collapse
Mechanism: Real-time biofeedback through mammalian co-regulation
Example: Equine-assisted therapy during neuroplastic windows. Horses provide immediate, non-verbal feedback on autonomic state, making implicit regulatory patterns explicit and modifiable

2. Predictive Updating (Cognitive Flexibility)

Target: Perseverative thinking, learned helplessness, cognitive rigidity
Mechanism: Structured prediction error exposure → model revision
Example: Accelerated Resolution Therapy (ART)—replacing catastrophic predictions with evidence-based alternatives during memory reconsolidation windows

3. Relational Repair (Social Coordination)

Target: Attachment wounding, relational constraint, isolation
Mechanism: Parts-based dialogue within coherent therapeutic frame
Example: Internal Family Systems (IFS)—externalizing conflicting drives → negotiating between protective strategies and core selfhood

4. Systemic Integration (Constraint Reduction)

Target: Environmental stressors, resource scarcity, role conflicts
Mechanism: Lifestyle architecture aligned with regulatory capacity
Example: Post-retreat planning around work, relationships, daily rhythms; reducing chronic constraint so new patterns can stabilize

When these four levels are coordinated (somatic recalibration, predictive updating, relational repair, and systemic integration) during the neuroplastic window opened by psychedelic medicine, something becomes possible that none achieves alone.

At Nāhua, we refer to this integration architecture as Directed Neuro Dynamics, a therapeutic framework designed to operate within known neuroplasticity windows. DND is the systematic coordination of interventions across somatic, cognitive, relational, and systemic levels during neuroplastic states to install adaptive regulatory patterns that remain stable after the window closes.

The Nāhua Model: Biology-Informed, Not Mysticism-Adjacent

Let me be clear about what we're not claiming:

• We're not claiming psychedelics are unnecessary (they're the most reliable plasticity-induction tool we have)
• We're not claiming mystical experiences are invalid (phenomenology matters, just not only phenomenology)
• We're not claiming genetics determine outcomes (high environmental modulation means context is paramount)

What we are claiming: Recent psychiatric genomics provides orthogonal validation for treatment models that prioritize state-dependent, multi-level intervention during neuroplastic windows.

This isn't about replacing mysticism with mechanism. It's about recognizing that mystical experience without integration architecture is neurobiologically incomplete—like inducing plasticity and then leaving the system to crystallize around whatever environmental pressures happen to be active.

At Nāhua Origins (opening 2027 in Costa Rica), we're building psychedelic-assisted therapy around this approach. It is designed for people experiencing treatment-resistant depression, anxiety, or PTSD, particularly those for whom SSRIs, talk therapy, or previous psychedelic experiences haven't produced lasting relief. Many of our guests are high-functioning individuals navigating what we call the Achievement Paradox (outward success masking regulatory exhaustion).

But our model is relevant for anyone whose system needs recalibration, not just symptom suppression. If you suspect your depression/anxiety reflects something deeper than "chemical imbalance," the genomics suggest you might be right.

Where This Goes Next

Your depression might not be a disease you have. It might be what happens when your nervous system's regulatory signaling degrades under sustained load.

The genetics back this up. The neuroscience backs this up. Clinical phenomenology backs this up.

What’s been missing is a treatment model that operationalizes this understanding to target the actual failure points rather than suppressing downstream symptoms.

That’s what we’re building.

Next in SLM 2: The Untethered Mind. We will explain how human cortical expansion, combined with the removal of real-world constraint, causes internal simulation to decouple from reality, producing rumination, anxiety, and cognitive instability.

Reference

Grotzinger, Andrew D., Josefin Werme, Wouter J. Peyrot, et al. 2026. “Mapping the Genetic Landscape across 14 Psychiatric Disorders.” Nature 649 (8096): 406–15.

Essays on treatment resistance, altered states, and the conditions under which change becomes possible.

Subscribe